22S Stock Overview
A medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Nuwellis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.46 |
| 52 Week High | US$51.45 |
| 52 Week Low | US$4.13 |
| Beta | 0.43 |
| 11 Month Change | 0% |
| 3 Month Change | -34.13% |
| 1 Year Change | -90.53% |
| 33 Year Change | -99.93% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22S | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.2% |
| 1Y | -90.5% | -3.5% | 13.3% |
Return vs Industry: 22S underperformed the German Medical Equipment industry which returned -1.5% over the past year.
Return vs Market: 22S underperformed the German Market which returned 7.6% over the past year.
Price Volatility
| 22S volatility | |
|---|---|
| 22S Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 22S's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 22S's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 59 | Nestor Jaramillo | www.nuwellis.com |
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Nuwellis, Inc. Fundamentals Summary
| 22S fundamental statistics | |
|---|---|
| Market cap | €2.17m |
| Earnings (TTM) | -€20.46m |
| Revenue (TTM) | €8.09m |
0.3x
P/S Ratio-0.1x
P/E RatioIs 22S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22S income statement (TTM) | |
|---|---|
| Revenue | US$9.01m |
| Cost of Revenue | US$3.58m |
| Gross Profit | US$5.43m |
| Other Expenses | US$28.25m |
| Earnings | -US$22.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.22 |
| Gross Margin | 60.28% |
| Net Profit Margin | -253.06% |
| Debt/Equity Ratio | 0% |
How did 22S perform over the long term?
See historical performance and comparison